Clinical trial
Fruquintinib Combined With AK104 and Tegafur Gimeracial and Oteracil as Second-ine or After Line Treatment in Advanced or Metastatic ESCC
NCT06487702 is registered in ClinicalTrials.gov with Rui-hua Xu, MD, PhD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fruquintinib Combined With AK104 and Tegafur Gimeracial and Oteracil as Second-ine or After Line Treatment in Advanced or Metastatic ESCC
- Lead sponsor
- Rui-hua Xu, MD, PhD
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 10, 2024
- Completion date
- June 10, 2027
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.